DnB Asset Management
INKT icon

DnB Asset Management’s MiNK Therapeutics INKT Stock Holding History

DnB Asset Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$645K Buy
+55,142
New +$642K ﹤0.01% 714

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

DnB Asset Management's INKT Position: Q2 2026 in Review

DnB Asset Management opened a new position in MiNK Therapeutics (INKT) in Q2 2026: 55,142 shares worth $645K. The stake represents ﹤0.01% of the portfolio and ranks #714 among its holdings.

22 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • DnB Asset Management held 55,142 shares of MiNK Therapeutics worth $645K as of Q2 2026.
  • MiNK Therapeutics was a new DnB Asset Management position in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #714 holding.
  • 22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.